Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Clinical trial NCT01269346 · COMPLETED
Trial details
- NCT number
- NCT01269346
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-12-01
- Primary completion
- 2013-03-01
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.